Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2666646 | 0.83 | MMP13 (0.43) | KMT2AMMP13MEN1 | |
| SCHEMBL1344659 | 0.82 | HTT (0.39) | ALDH1A1HTTPOLBGAAKMT2A | |
| SCHEMBL16799997 | 0.81 | MMP2 (0.44) | ALDH1A1MAPTHTTPOLBGAA | |
| SCHEMBL2643475 | 0.80 | ALDH1A1 (0.47) | ALDH1A1MAPTGAAKMT2A | |
| SCHEMBL4258524 | 0.79 | ALDH1A1 (0.40) | ALDH1A1HTTPOLBGAAKMT2A | |
| SCHEMBL4258522 | 0.79 | ALDH1A1 (0.40) | ALDH1A1HTTPOLBGAAKMT2A | |
| SCHEMBL13773434 | 0.78 | GCK (0.45) | ALDH1A1HTTPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL2652530 | 0.78 | GCK (0.45) | ALDH1A1HTTPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL2513636 | 0.77 | HTT (0.35) | ALDH1A1MAPTHTTPOLBGAA | |
| SCHEMBL10140953 | 0.77 | KMT2A (0.48) | ALDH1A1MAPTHTTPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402327-B1 | Acetamide compounds as glucokinase activators, their process and medicinal applications | IMPETIS BIOSCIENCES LTD (IN) | 2018-03-07 | — | — | EP | disclosed |
| US-9340506-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal applications | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-05-17 | — | — | US | disclosed |
| US-9340506-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal applications | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-05-17 | — | — | US | disclosed |
| US-9340506-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal applications | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-05-17 | — | — | US | disclosed |
| EP-2379517-B1 | Arylcyclopropylacetamide derivatives useful as glucokinase activators | LILLY CO ELI (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8501955-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2013-08-06 | — | — | US | disclosed |
| US-8501955-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2013-08-06 | — | — | US | disclosed |
| US-8501955-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2013-08-06 | — | — | US | disclosed |
| US-20120214735-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-08-23 | — | — | US | disclosed |
| US-20120214735-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-08-23 | — | — | US | disclosed |
| US-20090181981-A1 | CRYSTALLINE (R)-2-(4-CYCLOPROPANESULPHONYL-PHENYL)-N-PYRAZIN-2-YL-3-(TETRAHYDROPYRAN-4-YL)-PROPIONAMIDE | ELI LILLY AND COMPANY | 2009-07-16 | — | — | US | disclosed |
| US-20090181981-A1 | CRYSTALLINE (R)-2-(4-CYCLOPROPANESULPHONYL-PHENYL)-N-PYRAZIN-2-YL-3-(TETRAHYDROPYRAN-4-YL)-PROPIONAMIDE | ELI LILLY AND COMPANY | 2009-07-16 | — | — | US | disclosed |
| US-20090181981-A1 | CRYSTALLINE (R)-2-(4-CYCLOPROPANESULPHONYL-PHENYL)-N-PYRAZIN-2-YL-3-(TETRAHYDROPYRAN-4-YL)-PROPIONAMIDE | ELI LILLY AND COMPANY | 2009-07-16 | — | — | US | disclosed |
| US-20090005391-A1 | Tricyclo Substituted Amides | PROSIDION LIMITED (GB) | 2009-01-01 | — | — | US | disclosed |
| US-20090005391-A1 | Tricyclo Substituted Amides | PROSIDION LIMITED (GB) | 2009-01-01 | — | — | US | disclosed |
| US-20080015358-A1 | Fluorination Process of Protected Aminothiazole | PROSIDION LIMITED (GB) | 2008-01-17 | — | — | US | disclosed |
| US-20080015358-A1 | Fluorination Process of Protected Aminothiazole | PROSIDION LIMITED (GB) | 2008-01-17 | — | — | US | disclosed |
| WO-2007051845-A1 | TRICYCLO SUBSTITUTED AMIDES | PROSIDION LTD (GB) | 2007-05-10 | — | — | WO | disclosed |
| WO-2006016174-A1 | FLUORINATION PROCESS OF PROTECTED AMINOTHIAZOLE | PROSIDION LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006016178-A1 | ENANTIOSELECTIVE PROCESS | PROSIDION LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005391-A1 | Tricyclo Substituted Amides | GPR119, SLC5A2, SLC5A1 | ALDH1A1 1685/4885MAPT 2130/4885HTT 3026/4885 |
| US-20090181981-A1 | CRYSTALLINE (R)-2-(4-CYCLOPROPANESULPHONYL-PHENYL)-N-PYRAZIN-2-YL-3-(TETRAHYDROPYRAN-4-YL)-PROPIONAMIDE | PLP2, TUBA3C, TTR | ALDH1A1 3104/4885MAPT 191/4885HTT 846/4885 |
| US-20080015358-A1 | Fluorination Process of Protected Aminothiazole | GCK, KHK, GCKR | ALDH1A1 739/4885MAPT 2397/4885HTT 2386/4885 |
| US-20120214735-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS | GCK, GCKR, ALDOA | ALDH1A1 836/4885MAPT 324/4885HTT 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.